These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 29889811)

  • 21. Risk of Invasive Pneumococcal Disease in Children with Sickle Cell Disease in England: A National Observational Cohort Study, 2010-2015.
    Oligbu G; Collins S; Sheppard C; Fry N; Dick M; Streetly A; Ladhani S
    Arch Dis Child; 2018 Jul; 103(7):643-647. PubMed ID: 29282225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of the 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in infants younger than 90 days in England and wales.
    Ladhani SN; Andrews NJ; Waight P; Borrow R; Slack MP; Miller E
    Clin Infect Dis; 2013 Mar; 56(5):633-40. PubMed ID: 23175560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and non-invasive Streptococcus pneumoniae isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012-2014.
    Nakano S; Fujisawa T; Ito Y; Chang B; Suga S; Noguchi T; Yamamoto M; Matsumura Y; Nagao M; Takakura S; Ohnishi M; Ihara T; Ichiyama S
    Vaccine; 2016 Jan; 34(1):67-76. PubMed ID: 26602268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era.
    van der Linden M; Perniciaro S; Imöhl M
    BMC Infect Dis; 2015 May; 15():207. PubMed ID: 25940580
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early Streptococcus pneumoniae serotype changes in Utah adults after the introduction of PCV13 in children.
    Kendall BA; Dascomb KK; Mehta RR; Stockmann C; Mason EO; Ampofo K; Pavia AT; Byington CL
    Vaccine; 2016 Jan; 34(4):474-478. PubMed ID: 26706276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England.
    Southern J; Andrews N; Sandu P; Sheppard CL; Waight PA; Fry NK; Van Hoek AJ; Miller E
    PLoS One; 2018; 13(5):e0195799. PubMed ID: 29799839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis.
    Balsells E; Guillot L; Nair H; Kyaw MH
    PLoS One; 2017; 12(5):e0177113. PubMed ID: 28486544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics of children with invasive pneumococcal disease eligible for the 1+1 compared with the 2+1 PCV13 infant immunisation schedule in England: a prospective national observational surveillance study.
    Abdullahi F; Bertran M; D'Aeth JC; Eletu S; Chan YW; Andrews NJ; Litt DJ; Ramsay ME; Ladhani SN
    Lancet Child Adolesc Health; 2024 Nov; 8(11):788-797. PubMed ID: 39332425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England.
    Moore CE; Paul J; Foster D; Mahar SA; Griffiths D; Knox K; Peto TE; Walker AS; Crook DW;
    J Infect Dis; 2014 Oct; 210(7):1001-11. PubMed ID: 24719477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
    De Wals P; Lefebvre B; Deceuninck G; Longtin J
    Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales.
    Ladhani SN; Slack MP; Andrews NJ; Waight PA; Borrow R; Miller E
    Emerg Infect Dis; 2013 Jan; 19(1):61-8. PubMed ID: 23259937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in molecular epidemiology of streptococcus pneumoniae causing meningitis following introduction of pneumococcal conjugate vaccination in England and Wales.
    Pichon B; Ladhani SN; Slack MP; Segonds-Pichon A; Andrews NJ; Waight PA; Miller E; George R
    J Clin Microbiol; 2013 Mar; 51(3):820-7. PubMed ID: 23269742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.
    Mokaddas E; Albert MJ
    Vaccine; 2012 Dec; 30 Suppl 6():G37-40. PubMed ID: 23228356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines.
    Dion SB; Major M; Gabriela Grajales A; Nepal RM; Cane A; Gessner B; Vojicic J; Suaya JA
    Vaccine; 2021 May; 39(22):3007-3017. PubMed ID: 33824041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serotype distribution and antimicrobial susceptibilities of nasopharyngeal isolates of Streptococcus pneumoniae from healthy children in the 13-valent pneumococcal conjugate vaccine era.
    Zuccotti G; Mameli C; Daprai L; Garlaschi ML; Dilillo D; Bedogni G; Faccini M; Gramegna M; Torresani E; ; Ballerini E; Benincaso A; Bonvissuto M; Bricalli D; Brioschi M; Calloni CS; Camiletti MI; Colella G; De Angelis L; Decarlis S; Di Nello F; Dozzi M; Galli E; Gandini V; Giuliani MG; Laviola F; Loda B; Macedoni M; Mazzucchi E; Metta MG; Moscatiello A; Nannini P; Petruzzi M; Picicco D; Picciotti M; Pisanelli S; Porta N; Ramponi G; Redaelli F; Rubini R; Sala N; Saitta V; Scelza G; Tiso RM; Tomasetto M; Torcoletti M; Travaini M; Valentini M; Vessia C
    Vaccine; 2014 Jan; 32(5):527-34. PubMed ID: 24342249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In-depth analysis of pneumococcal serotypes in Belgian children (2015-2018): Diversity, invasive disease potential, and antimicrobial susceptibility in carriage and disease.
    Desmet S; Wouters I; Heirstraeten LV; Beutels P; Van Damme P; Malhotra-Kumar S; Maes P; Verhaegen J; Peetermans WE; Lagrou K; Theeten H
    Vaccine; 2021 Jan; 39(2):372-379. PubMed ID: 33308889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska.
    Bruce MG; Singleton R; Bulkow L; Rudolph K; Zulz T; Gounder P; Hurlburt D; Bruden D; Hennessy T
    Vaccine; 2015 Sep; 33(38):4813-9. PubMed ID: 26247901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distribution of invasive Streptococcus pneumoniae serotypes before and 5 years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil.
    Brandileone MC; Almeida SCG; Minamisava R; Andrade AL
    Vaccine; 2018 May; 36(19):2559-2566. PubMed ID: 29650385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine.
    Miller E; Andrews NJ; Waight PA; Slack MP; George RC
    Vaccine; 2011 Nov; 29(49):9127-31. PubMed ID: 21983361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.